# Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

> **NCT00135200** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Iodine I 131 Tositumomab

## Key facts

- **NCT ID:** NCT00135200
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2013-08
- **Final completion:** 2024-09-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135200, "Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00135200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*